Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Medicines Patent Pool

Pharma's expensive gaming of the drug patent system is successfully countered by the Medicines Patent Pool, which increases global access and rewards innovation

Biomedical innovation reached a new era during the COVID-19 pandemic as drug development went into overdrive. But the ways that brand companies license their patented drugs grant them market monopoly, preventing other entities from making generics so they can exclusively profit. This significantly limits the reach of lifesaving drugs, especially…

The Conversation

Leading figures urge drugs firm to lower price of ‘game-changing’ HIV prevention drug

Signatories including Olly Alexander, Stephen Fry and Joseph Stiglitz issue a letter asking ViiV to make cabotegravir affordable to low- and middle-income countries

The Guardian - UK

Price Of Pfizer's Paxlovid Generic Version Capped At $25 Or Less For Low-Income Countries

Several generic drugmakers will produce cheaper versions of Pfizer Inc's (NYSE:PFE) COVID-19 antiviral treatment Paxlovid at $25/course or less for low- and middle-income countries, Reuters reported citing the Clinton Health Access Initiative (CHAI). CHAI said it could not disclose the manufacturers' names who have agreed to the price ceiling because they are still in…

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Poor nations left behind on vaccines

"Do not let history repeat itself," advocates warn as low-income countries lack access to Pfizer treatment

Salon

Hyderabad cos get licence for Pfizer’s Covid pill

HYDERABAD: Apart from Hyderabad-based pharma major Aurobindo Pharma Limited, other city-based pharma players like Granules India Ltd, MSN Group and SMS Pharmaceuticals too have received licences from the UN-backed Medicines Patent Pool (MPP) to manufacture and supply a generic version of nirmatrelvir, a key component of Pfizer’s oral Covid-19 drug…

The Times of India

Aurobindo gets licence for supply of Pfizer’s Covid pill

HYDERABAD: Pharma major Aurobindo Pharma Limited has inked a sub-license agreement with the United Nations-backed public health organisation Medicines Patent Pool (MPP) for manufacturing and supplying a generic version of Pfizer’s oral Covid-19 treatment drug nirmatrelvir to 95 countries, including India.

The Times of India

19 firms in India to make Pfizer’s oral COVID-19 antiviral drug

They have signed sublicence agreements with United Nations-backed Medicines Patent Pool

The Hindu

Read news from The Economist, FT, and more,
with one subscription

35 Generic Drugmakers Sign To Manufacture Low-Cost Version Of Pfizer's COVID Pill

Thirty-five generic drugmakers will produce low-cost versions of Pfizer Inc's (NYSE:PFE) COVID-19 pill, Paxlovid, to expand supplies of the highly effective drug in lower-income regions. Pfizer struck a deal last year with the group to allow generic drugmakers to make the pills for 95 low- and middle-income countries, covering up to approximately 53% of the…

Benzinga

More than 30 companies to start making Pfizer's COVID pill

The U.N.-backed Medicines Patent Pool says that nearly three dozen companies worldwide will soon start making generic versions of Pfizer’s coronavirus pill

The Independent UK

Pfizer Commits 10M Courses Of COVID-19 Oral Antiviral To Developing Countries: Reuters

Pfizer Inc (NYSE:PFE) is expected to provide around 10 million courses of its highly effective COVID-19 antiviral treatment Paxlovid to low- and middle-income countries in 2022, reports Reuters citing an official with the Global Fund. The Fund's head of strategy for policy, Harley Feldbaum, said Pfizer had committed at least that many…

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Teva Pharmaceutical Industries Ltd

13 stories

Medicines Patent Pool

10 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.